5.90
-0.30
(-4.84%)
At close: January 30 at 5:24:48 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-17,335.00
-19,925.00
-16,735.00
-15,251.00
-12,092.00
Investing Cash Flow
545.00
13,881.00
19,914.00
13,406.00
-49,595.00
Financing Cash Flow
7,081.00
5,449.00
1,114.00
1,512.00
68,488.00
Cash Flow from Discontinued Operation
--
--
--
-374.00
--
End Cash Position
5,395.00
14,489.00
15,030.00
10,890.00
11,247.00
Capital Expenditure
--
-3.00
-228.00
-115.00
-156.00
Issuance of Capital Stock
1,446.00
1,563.00
1,498.00
564.00
27,925.00
Repayment of Debt
-177.00
-168.00
-165.00
-153.00
-179.00
Free Cash Flow
-17,335.00
-19,928.00
-16,963.00
-15,366.00
-12,248.00
12/31/2020 - 8/12/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ORMP.TA Oramed Pharmaceuticals Inc.
796.60
-0.75%
ENLV.TA Enlivex Therapeutics Ltd.
396.00
-0.63%
LCTX.TA Lineage Cell Therapeutics, Inc.
223.00
-5.55%
EVGN.TA Evogene Ltd.
551.10
-3.49%
XTLB XTL Biopharmaceuticals Ltd.
1.5899
-1.25%
BLRX.TA BioLineRx Ltd.
2.4000
-25.00%
ENLV Enlivex Therapeutics Ltd.
1.1000
-0.90%
ORMP Oramed Pharmaceuticals Inc.
2.2400
+1.82%
ANRO Alto Neuroscience, Inc.
4.2900
-3.81%
RLMD Relmada Therapeutics, Inc.
0.3490
-1.41%